KAINOS Laboratories, INC.

4556・Standard Market・Pharmaceuticals

Official website

KAINOS Laboratories, INC.

4556・Standard Market・Pharmaceuticals

Official website

KAINOS Laboratories, INC.4556

Reference Indicators

Market Cap

—

P/E (Forecast)

—

P/B

—

Dividend Yield (Forecast)

—

ROE

6.4%

EV/EBITDA

—

Financial Summary

Unit: ¥M

Item	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Net Sales	4,614	4,923	5,056	5,305	5,479
Cost of Sales	2,207	2,409	2,504	2,631	2,887
Gross Profit	2,407	2,513	2,551	2,674	2,592
SG&A Expenses	1,659	1,692	1,686	1,850	1,844
Operating Income	747	821	865	823	747
Non-operating Income	42	40	106	13	80
Non-operating Expenses	11	8	43	8	39
Ordinary Income	777	853	928	828	788
Extraordinary Income	—	—	3	0	0
Extraordinary Losses	10	8	2	1	154
Pre-tax Income	767	845	930	827	634
Income Taxes	254	276	292	186	185
Net Income	512	568	637	641	449
EBITDA	897	962	983	926	850
Gross Margin	52.2%	51.1%	50.5%	50.4%	47.3%
Operating Margin	16.2%	16.7%	17.1%	15.5%	13.6%
ROA	6.8%	7.0%	7.4%	7.3%	4.7%
ROE	10.4%	10.5%	10.7%	9.8%	6.4%